Clinical trials: Monoclonal
Advanced Solid Tumor
A Study of HY-0102 in Patients With Advanced Solid Tumors
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of HY-0102 administered intravenously (IV) once every two weeks in patients with advanced solid tumors, so as to confirm…
- Trial name
- NCT06094777
- Testing
- HY-0102
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Myelodysplastic Syndrome (MDS)
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
This study is a phase I, open-label, single-arm, dose escalation trial to determine the safety and activity of lenalidomide combined with lintuzumab in patients with MDS.
- Trial name
- NCT00502112
- Testing
- lintuzumab, lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Seagen Inc.
Healthy Subjects
A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
This is a proof-of-concept study to investigate whether antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation.
- Trial name
- NCT07788807
- Testing
- Adalimumab, Guselkumab, SDL-001
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Surmount Services, Inc.
Psoriatic Arthritis
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
This study is designed as an extension study to the proof-of-concept trial CAIN457A2206 in patients with psoriatic arthritis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety…
- Trial name
- NCT01169844
- Testing
- AIN457A, Other
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Postural Orthostatic Tachycardia Syndrome (POTS)
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is.
- Trial name
- PINNACLE (NCT06593600)
- Testing
- REGN7544
- Where
- 16 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Regeneron Pharmaceuticals
Mantle Cell Lymphoma
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.
- Trial name
- NCT00022945
- Testing
- Iodine-131 Anti-B1 Antibody, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
- Where
- 3 sites in United States
- Sponsor
- Corixa Corporation
Hereditary Angioedema
Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers
It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-038.
- Trial name
- NCT04557319
- Testing
- GNR-038, 25 МЕ/kg, GNR-038, 50 МЕ/kg, GNR-038, 100 МЕ/kg
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM
Rheumatoid Arthritis
Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
The purpose of this study is to determine if MDX-1342 given in combination with Methotrexate is a safe treatment for patients with active rheumatoid arthritis.
- Trial name
- MDX1342-01 (NCT00639834)
- Testing
- MDX-1342
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 26 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Follicular
HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
A Single-Arm, International, Multi-Center Trial of HuMax-CD20 (Ofatumumab), a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With…
- Trial name
- NCT00394836
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007826
- Testing
- BCG vaccine, monoclonal antibody 105AD7 anti-idiotype vaccine, alum adjuvant
- Where
- United Kingdom
- Sponsor
- Onyvax
Diffuse Large B Cell Lymphoma
Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma
CD20, the protein which is expressed on the surface of all mature B cells, is active in many B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL), the most frequently occurring subtype of…
- Trial name
- NCT01459887
- Testing
- CHOP combined with CMAB304, CHOP, CMAB304
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Drug Safety
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Primary To evaluate the safety and tolerability of escalating doses of an intravenous (i.v.) infusion of PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT01727778
- Testing
- Anti-GRP78 monoclonal IgM antibody PAT-SM6
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Patrys Ltd.
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with…
- Trial name
- NCT01689532
- Testing
- Sirukumab 100 mg, Sirukumab 50 mg
- Where
- 17 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Janssen Pharmaceutical K.K.
Plasma Cell Myeloma
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of…
- Trial name
- IKEMA (NCT03275285)
- Testing
- isatuximab SAR650984, carfilzomib, dexamethasone
- Where
- 70 sites in United States, Australia and 14 more
- Volunteers
- 302 people
- Sponsor
- Sanofi
Influenza, Human
Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza
The purpose of this study is to compare the safety profile in healthy volunteers of a single intravenous administration of TCN-032 as compared with placebo.
- Trial name
- NCT01390025
- Testing
- TCN-032
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theraclone Sciences, Inc.
Multiple Myeloma
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Primary Objective: To evaluate the pharmacokinetics (PK) of isatuximab. Secondary Objectives: To evaluate the safety and tolerability of isatuximab. To assess the preliminary antitumor effect of isatuximab.
- Trial name
- NCT03733717
- Testing
- Isatuximab SAR650984
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
The aim of this Phase I/IIa study is to identify a safe and tolerable dosage regimen of intravenously administered otelixizumab.
- Trial name
- NCT02000817
- Testing
- Otelixizumab
- Where
- 6 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Ovarian Neoplasms
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and…
- Conditions
- Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
- Trial name
- NCT01279291
- Testing
- KHK2866, Gemcitabine and Carboplatin, paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Small Cell Lung Cancer
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal…
- Trial name
- NCT06500026
- Testing
- BL-B01D1, Topotecan
- Where
- China
- Volunteers
- 722 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.